Accéder au contenu
Merck

Differential substitution for the discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and methylphenidate in rats.

The Journal of pharmacology and experimental therapeutics (2014-06-12)
Tomohisa Mori, Naoki Uzawa, Haruyo Kazawa, Hirohiko Watanabe, Ayano Mochizuki, Masahiro Shibasaki, Kazumi Yoshizawa, Kimio Higashiyama, Tsutomu Suzuki
RÉSUMÉ

Previous studies have demonstrated that methylphenidate, MDMA (3,4-methylenedioxymethamphetamine), and other psychostimulants exert stimulant-like subjective effects in humans. Furthermore, MDMA and methylphenidate substitute for the discriminative stimulus effects of psychostimulants, such as amphetamine and cocaine, in animals, which suggests that MDMA and methylphenidate may produce similar discriminative stimulus effects in rats. However, there is no evidence regarding the similarities between the discriminative stimulus effects of MDMA and methylphenidate. To explore this issue, cross-substitution, substitution, and combination tests were conducted in rats that had been trained to discriminate between MDMA (2.5 mg/kg) or methylphenidate (5.0 mg/kg) and saline. In the cross-substitution tests, MDMA and methylphenidate did not cross-substitute for each other. In the substitution test, methamphetamine substituted for the discriminative stimulus effects of methylphenidate, but not for those of MDMA. Furthermore, ephedrine and bupropion, which activate dopaminergic and noradrenergic systems, substituted for the discriminative stimulus effects of methylphenidate. On the other hand, serotonin (5-HT) receptor agonists 5-HT1A and 5-HT2 fully substituted for the discriminative stimulus effects of MDMA. These results suggest that activation of the noradrenergic and dopaminergic systems is important for the discriminative stimulus effects of methylphenidate, whereas activation of the serotonergic system is crucial for the discriminative stimulus effects of MDMA. Even though MDMA, like psychostimulants, exerts stimulant-like effects, our findings clearly indicate that the discriminative stimulus effects of MDMA are distinctly different from those of other psychostimulants in rats.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Fluoxétine hydrochloride, solid
Supelco
(±)-MDMA solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Prazosin hydrochloride, ≥99.0% (HPLC)
Sigma-Aldrich
Desipramine hydrochloride, ≥98% (TLC), powder
Sigma-Aldrich
Haloperidol, powder
Sigma-Aldrich
R-(−)-Apomorphine hydrochloride hemihydrate, calcined, ≥98.5% (with NaOH, titration)
Supelco
Fluoxétine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methylphenidate hydrochloride solution, (Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material, Cerilliant®
USP
Fluvoxamine maleate, United States Pharmacopeia (USP) Reference Standard
Supelco
Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
USP
Fluoxétine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Fluvoxamine maleate, solid
USP
Haloperidol, United States Pharmacopeia (USP) Reference Standard
USP
Bupropion hydrochloride, United States Pharmacopeia (USP) Reference Standard
USP
Desipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
USP
Prazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Apomorphine hydrochloride hemihydrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Fluoxétine hydrochloride, VETRANAL®, analytical standard
Haloperidol, European Pharmacopoeia (EP) Reference Standard
Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Prazosin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard
Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard
Fluvoxamine maleate, European Pharmacopoeia (EP) Reference Standard
Fluvoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard